<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

CD3E Transgenic Mouse Model for Bispecific Antibody Testing

T cell-redirecting therapy is taking a prominent role in immuno-oncology. Recent research has involved the development of T cell-redirecting bispecific antibodies, which bind to a specific tumor associated antigen (TAA) on tumor cells and CD3 (usually epsilon chain, CD3ε) on T cells.